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Abstract
Background: Mast cells and basophils are multifunctional effector cells and contain plentiful secretary granules in their
cytoplasm. These cell types are involved in several inflammatory and immune events and are known to produce an array
of mediators including a broad spectrum of cytokines. Pomegranate fruit is rich in anthocyanins and hydrolysable tannins;
a group of polyphenolic compounds shown to be potent antioxidant with anti-inflammatory activity. However, no studies
have been undertaken to investigate whether a polyphenol-rich pomegranate fruit extract (POMx) inhibits the
inflammatory activity of activated human mast cells and basophils. The aim of this study was to examine whether POMx
modulates inflammatory reactions using human basophilic cell line KU812.
Methods: KU812 cells were stimulated with phorbol-12-myristate 13-acetate plus calcium inophore A23187 (PMACI).
The inhibitory effect of POMx on pro-inflammatory cytokine gene expression and production by stimulated KU812 cells
was measured by quantitative RT-PCR, and cytokine-specific ELISA assays, respectively. Western blotting was used to
analyze the effect of POMx on the activation of mitogen-activated protein kinases (MAPKs), and the nuclear factor (NF)-
κB in PMACI stimulated KU812 cells. Effect on the activity of NF-κB was determined using Luciferase reporter assay.
Significance of differences from control values were analyzed by means of standard statistical methods.
Results: POMx significantly decreased PMACI stimulated inflammatory gene expression and production of interleukin
(IL)-6 and IL-8 in KU812 cells. The inhibitory effect of POMx on the pro-inflammatory cytokines was MAPK subgroups
c-jun N-terminal kinase (JNK)- and extracellular-regulated kinase (ERK) dependent. In addition, POMx suppressed the
NF-κB activation induced by PMACI by inhibiting IκB-degradation in human basophil cells. POMx also suppressed the
powerful induction of NF-κB promoter-mediated luciferase activity in transiently transfected KU812 cells.
Conclusion: These novel pharmacological actions of POMx provide new suggestion that POMx or POMx-derived
compounds may be of therapeutic use for the treatment of inflammatory diseases by suppressing mast cells/basophils
activation.
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Background
Mast cells and basophils are known to play a central role
in inflammatory and immune events [1]. Mast cells –
derived mediators induce edema, destroy connective tis-
sue, and are involved in lymphocyte chemotaxis and infil-
tration and in pathological fibrosis in rheumatoid
arthritis (RA) joints. Moreover, these cells are involved in
angiogenesis during inflammatory arthritis, and the pro-
teolytic activity they produce is associated with cartilage
destruction and bone remodeling [2]. The myeloid pre-
cursor cell line KU812 originally established from a
patient with chronic myelogenous leukemia (CML) [3]
has been shown in several published studies [4,5] to be a
suitable model for studying the activation and degranula-
tion of human mast cells [5-7]. Activation of these cells
results in the degranulation accompanied by the produc-
tion of chemical mediators such as histamine, proteases,
metabolites of arachidonic acid and several inflammatory
and chemotactic cytokines including interleukin (IL)-6
and IL-8. These molecules act on the vasculature, smooth
muscle, connective tissue, and mucous glands, resulting
in the recruitment of activated immune and inflammatory
cells to the site of inflammatory lesion, thereby amplify-
ing and sustaining the inflammatory condition [8]. The
pro-inflammatory cytokines produced by the mast cells
and basophils play an important role in the development
of acute- and late-phase inflammatory reactions. Produc-
tion of TNF-α, IL-6, IL-8, histamine and other inflamma-
tory mediators by the activated mast cells could drive
synovitis in RA [9,10], and it has been shown that mice
deficient in mast cell activation were resistant to the
induction of arthritis in the K/BXN model of rheumatoid
arthritis [11]. These data suggest that inhibition of mast
cell/basophil function could provide benefit in RA and
other inflammatory diseases.
Mitogen-activated protein kinases (MAPKs) activated by
various stimuli regulate the transcriptional activity of
many genes involved in maintaining cellular homeosta-
sis. Depending on the extracellular stimuli cell com-
mences specific biological responses leading to
differentiation, proliferation or apoptosis through the
activation of MAPK signaling cascades. Activation of extra-
cellular signal-regulated kinase (ERK), and c-Jun N-termi-
nal kinase (JNK) by environmental stimuli play a
significant role in the cytokine expression and appear to
play an important regulatory role in inflammatory dis-
eases including RA [12,13]. Nuclear factor (NF)-κB is a
ubiquitously expressed transcription factor required for
the expression of a number of inflammatory molecules
[14] including TNF-α, IL-1β, and IL-6 [15]. For this rea-
sons, NF-κB is an obvious target of emerging anti-inflam-
matory therapies [16].
Pomegranate (Punica granatum L, Punicaceae), is an edi-
ble fruit cultivated in many countries, including the
United States and consumed around the world. It is well
documented that the edible part of pomegranate is rich in
anthocyanins and hydrolysable tannins, a group of
polyphenolic compounds that possess antioxidant and
anti-inflammatory activities [17]. Recently, pomegranate
juice was found to revert the potent down regulation of
the expression of endothelial nitric oxide synthase
induced by oxidized low-density lipoprotein in human
coronary endothelial cells [18]. Dietary supplementation
of polyphenolic rich pomegranate extract to atheroscle-
rotic mice was shown to inhibit significantly the develop-
ment of atherosclerotic lesions [19]. It has also been
shown that pomegranate extract can suppress NF-κB acti-
vation in vascular endothelial cells [20].
Recent studies from our laboratory have demonstrated
that consumption of pomegranate may be of value in
inhibiting inflammatory stimuli-induced cartilage break-
down and production of inflammatory mediators in
arthritis and it may be a useful approach for the preven-
tion of the onset and severity of inflammatory arthritis
[21,22]. In the present study, we evaluated the potential of
a standardized pomegranate fruit extract (POMx) as a
therapeutic modality for inflammation using PMACI-
stimulated human KU812 cells. Our results showed that
POMx significantly inhibited the inflammatory stimuli-
induced excessive production of IL-6 and IL-8 via modu-
lation of the JNK- and ERK-MAPKs and NF-κB-dependent
pathways.
Methods
Reagents and cell lines
Phorbol 12-myristate 13-acetate (PMA), calcium iono-
phore A23187 (Calcymycin; C29H37N3O6) were pur-
chased from Sigma Chemical Co. (St. Louis, MO), and
dissolved in DMSO. KU812 cells, RAW264.7 cells, RPMI-
1640, DMEM were from American Type Culture Collec-
tion (ATCC) (Rockville, MD, USA). Antibodies were pur-
chased from Cell Signaling Technology (Denver's, MA,
USA) and Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Specific inhibitors for ERK (PD98059), and JNK
(SP600125) were purchased from Biomol (Plymouth
Meeting, PA). Inhibitor for NF-κB (MG-132) was pur-
chased from Calbiochem (San Diego, CA, USA) Kits for
performing cytokine specific enzyme-linked immuno-
sorbent assays (ELISA) were purchased from R&D Systems
(St. Paul, MN, USA). All other reagents/chemicals were of
the highest analytical grade available.
Chemical composition of POMx
POMx was produced from fresh pomegranate fruits
(Punica granatum L., POM Wonderful brand) grown in
California by Paramount Farms and was prepared byJournal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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extraction of fruit residue after pressing for juice and solid-
phase extraction to produce a powder with a high concen-
tration of polyphenols. The powder extract used in this
study contained on average 86.0% ellagitannins, 2.5%
ash, 3.2% sugars, 1.9% organic acids as citric acid equiva-
lents, 0.8% nitrogen, and 1.2% moisture. The approxi-
mate percent distribution of pomegranate polyphenols in
POMx is as follows: 19% ellagitannins as punicalagins
and punicalins, 4% free ellagic acid, and 77% oligomers
composed of 2–10 repeating units of gallic acid, ellagic
acid, and glucose in different combinations.
Cell culture
KU812 cells were grown in RPMI-1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS) and 1% penicillin-streptomycin at 37°C in 5%
CO2. KU812 cells were pre-treated with POMx (20–100
μg/ml) for two hour prior to stimulation with 40 nM of
PMA plus 1 μM of A23187 for different periods of time.
POMx was dissolved in nuclease free double filtered dis-
tilled water, whereas PMA and A23187 were dissolved in
DMSO.
Real Time-PCR
Real time polymerase chain reaction (qRT-PCR) was used
to quantify the expression of mRNA for IL-6 and IL-8 with
expression of GAPDH as control. Total RNA was separated
from KU812 cells by Quick Gene automated system
according to the manufacturer's instruction (Quick Gene,
USA). First-strand cDNA was synthesized using 1 μg total
RNA and the SuperScript First Strand cDNA synthesis kit
(Invitrogen, USA). Primers used were: IL-6 (F 5'-AAA TTC
GGT ACA TCC TCG ACG GCA-3'; R 5'-AGT GCC TCT TTG
CTG CTT TCA CAC-3'), and IL-8 (F 5'-AGA AAC CAC
CGG AAG GAA CCA TCT-3'; R 5'-AGA GCT GCA GAA
ATC AGG AAG GCT-3'); GAPDH (F 5'-GGA CTT CGA
GCA AGA GAT-3'; R 5'-AGC ACT GTG TTG GCG TAC-3').
The amplification was performed using the qPCR core kit
for SYBR Green (Qiagen, USA) and Step One Real Time
system PCR (Applied Biosystems, Foster City, CA). Typical
profile times used were initial step, 95°C for 15 min, fol-
lowed by a second step at 94°C for 15 sec, 60°C for 30 sec
and 72°C for 30 sec for 40 cycles with melting curve anal-
ysis. The level of target mRNA was normalized to the level
of GAPDH and compared to control (untreated sample)
and the values were calculated by 2-ΔΔCT method, where
ΔCT is the difference in threshold cycles for target and the
housekeeping gene, and ΔΔCT is the differences in ΔCT
and the threshold cycle for the control [23].
Enzyme-linked immunosorbent assay (ELISA)
Cytokines produced in the culture medium were quanti-
fied by specific sandwich ELISAs. Briefly, KU812 cells were
stimulated with PMA (40 nM) plus A23187 (1 μM) for 12
h with or without pre-treatment with POMx. The ELISA
was performed using the culture supernatants according
to the instructions of the manufacturer (R&D Systems).
Plates were read at 450 nm using Synergy HT microplate
reader (Biotek Instruction, Winooski, VT, USA).
Western blot analysis
Stimulated and control KU812 cells were washed with
cold PBS and lysed using the cell lysis buffer (50 mM
Tris:HCl, pH 7.4; 150 mM NaCl; 1% Triton X-100; 0.1%
SDS; 0.5% sodium deoxycholate; 1 mM EDTA; 1 mM
EGTA; Complete® protease and phosphatase inhibitors) as
previously described [24]. Cytoplasmic and nuclear frac-
tions were prepared as previously described [25]. Total
lysate or nuclear/cytoplasmic fraction protein (45 μg/
lane) was resolved by SDS-PAGE (10% resolving gel with
4% stacking) and transferred to nitrocellulose membranes
(Bio-Rad). Membranes were blocked with blocking buffer
containing non-fat dry milk powder in Tris buffered saline
containing 0.1% Tween-20 (TBS-T), and probed with 1:
1000 diluted primary antibodies (Cell Signaling Technol-
ogies, Santa Cruz Biotechnology) specific for the target
protein. Immunoreactive proteins were visualized by
using 1:5000 diluted HRP-linked secondary antibodies
and enhanced chemiluminescence (GE Healthcare, Mil-
waukee, WI, USA) [26]. Images were captured by using
AFP-Imaging System (Minimedical Series, Elms Ford, NY,
USA).
Transient transfection and luciferase activity assay
Transient transfection and luciferase activity assay were
performed as previously described [21]. Briefly, KU812
cells were seeded at 3 × 106 cells ml-1 in 12-well plate 4 h
before the transfection in serum-free medium. Lipo-
fectamin 2000 reagent (Invirtogen, Carlsbad, CA) con-
taining the NF-κB luciferase reporter gene constructs,
pNF-κB-LUC (Panomics) was added to the cell cultures
according to the instructions of the manufacturer (Invitro-
gen, Carlsbad, CA). After 6 h of incubation, medium was
replaced with fresh medium containing 10% FBS and
antibiotics. Transfected KU812 cells were stimulated with
PMACI for 20 h. In some experiments POMx (20–100 μg/
ml) was added to the cultures for 2 h prior to PMACI-stim-
ulation. Cells were harvested after 20 h stimulation and
washed in ice-cold PBS before lysis in 100 μl of cell lysis
buffer and the luciferase activity was determined accord-
ing to the manufacturer's protocol (Luciferase Assay kit;
Promega, Madison, WI), using a Lumat LB 9507 [Lumi-
nometer] Berthold Technologies, Germany). Luciferase
activity was expressed as relative light units (RLU) per mil-
ligram of cell lysate protein.
Statistical analysis
All statistical analyses were performed using Origin 6.1
software package (one paired two tailed t-test with oneJournal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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way ANOVA) and P < 0.05 was considered significant.
Values shown are mean ± SD unless stated otherwise.
Results
Effect of POMx on cell viability and pro-inflammatory 
cytokines expression in activated KU812 cells
We first examined the cytotoxicity of POMx on KU812
cells using Trypan Blue assay. POMx did not show cyto-
toxic effect up to a concentration of 300 μg/ml (data not
shown). Next, we examined whether POMx could modu-
late gene expression of pro-inflammatory cytokines IL-6,
and IL-8 induced by PMACI in KU812 cells. For these
studies cells were pretreated with POMx (20–100 μg/ml)
for 1 h, then stimulated with PMA (40 nM) plus A23187
(1 μM) for 4 h. As shown in Fig. 1A, and Fig. 1B, pretreat-
ment with POMx dose dependently inhibited PMACI-
induced gene expression of IL-6 and IL-8 as determined by
quantitative RT-PCR. To confirm the effect of POMx on
the production of pro-inflammatory cytokines, culture
supernatants were assayed for cytokine levels using
cytokine-specific ELISA. As shown in Fig. 2A and 2B, pre-
treatment with 20–100 μg/ml of POMx significantly
decreased the PMACI-induced IL-6 and IL-8 production in
the culture supernatant of activated KU812 cells.
Effect of POMx on the activation of MAPK
Activation of MAPKs is intimately associated with the
expression of pro-inflammatory cytokines. To determine
whether the inhibition of IL-6 and IL-8 expression was
mediated by inhibition of MAPK, we examined the effect
of POMx on the activation of MAPKs in KU812 cells.
KU812 cells were pretreated with POMx (20–100 μg/ml)
for 1 h and then stimulated with PMACI for 2 h and cell
lysate was analyzed by Western immunoblotting. Pre-
treatment of KU812 cells with POMx attenuated the
PMACI-induced phosphorylation of JNKp54/p46- and
ERKp44/p42 (Fig. 3). No effect on p38-MAPK was
observed (data not shown).
To further strengthen the relation of JNK- and ERK-inhibi-
tion by POMx and proinflammatory cytokines expres-
sions in KU812 cells, we investigated the effects of
pharmacological agents that inhibit JNK- and ERK. Treat-
ment of KU812 cells with the selective JNK inhibitor,
SP600125 (50 μM), and ERK inhibitor, PD98059 (10
μM), blocked the PMA plus A23187-induced IL-6 and IL-
8 gene expression as determined by quantitative RT-PCR
(Fig. 1A &1B). These data support the contention that
inhibition of IL-6 and IL-8 expression by POMx in KU812
cells (Fig. 1A &1B) was mediated, at least in part, by the
inhibition of PMACI-induced activation of JNK and ERK
pathways.
Effect of POMx on NF-κB activation
NF-κB is an important transcriptional regulator of inflam-
matory cytokines gene expression and plays a crucial role
in immune and inflammatory responses. After the ubiqui-
tination and phosphorylation of IκBα, the inhibitor is
degraded and the NF-κB is translocated to the nucleus
where it binds and activate the promoter of target genes.
To further investigate the mechanism responsible for the
inhibitory effect of POMx on pro-inflammatory cytokine
expression such as IL-6, and IL-8, we examined the effect
of POMx on NF-κB activation and translocation to the
nucleus using Western blotting. Stimulation of KU812
cells with PMA plus A23187 induced the degradation of
IκBα and nuclear translocation of p65 NF-κB (Fig 4A
&4B). Pretreatment with POMx (20–100 μg/ml) inhibited
the PMA plus A23187-induced degradation of IκBα and
nuclear translocation of p65 NF-κB (Fig 4A &1B) in
KU812 cells.
To determine whether POMx also inhibit DNA binding
activity of NF-κB, we used a NF-κB-dependent gene
reporter assay. KU812 cells were transiently transfected
with a NF-κB-luciferase reporter construct or the empty
vector. Exposure of cells to PMA plus A23187 enhanced
the luciferase activity several fold in the cells transfected
with the NF-κB-luciferase reporter construct. Increasing
doses of POMx (20–100 μg/ml) significantly reduced the
PMA plus A23187-induced luciferase activity (Fig. 4C). To
further strengthen the relation of NF-κB pathway and the
expression of IL-6 and IL-8 in KU812 cells, we next inves-
tigated the effect of a pharmacological agent, MG-132, a
known inhibitor of NF-κB, on the expression of IL-6 and
IL-8. Treatment of cells with the proteasome inhibitor
MG-132 (100 μM), blocked the PMACI-induced IL-6 and
IL-8 expression as determined by quantitative RT-PCR
(Fig. 1A &1B). Together these results suggest that POMx
exert its inhibitory effect on IL-6 and IL-8 expression via
modulation of the activation and DNA binding activity of
NF-κB.
Discussion
Mast cells are emerging key players in the erosive and
inflammatory events leading to joint destruction in
inflammatory arthritis. Accumulation of mast cells in
rheumatoid synovial tissue and their activation and deg-
radation associated with pro-inflammatory cytokines and
matrix degrading enzymes at cartilage erosion sites sug-
gest that they could be usefully selected as a therapeutic
target [2]. Mast cells are known to play a central role in
inflammatory diseases as these cells contain potent
inflammatory mediators, including histamine, heparin,
proteinases, leukotrienes, and multifunctional cytokines,
and their potential contributions to processes of inflam-
mation and matrix degradation have become evident
[27,28]. In response to diverse stimuli, human basophilicJournal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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Effect of POMx and specific inhibitors for MAPKs and NF-κB on the gene expression of pro-inflammatory cytokines in PMACI- stimulated KU812 cells Figure 1
Effect of POMx and specific inhibitors for MAPKs and NF-κB on the gene expression of pro-inflammatory 
cytokines in PMACI-stimulated KU812 cells. KU812 cells (3 × 106 cells ml-1) were pretreated with POMx (20–100 μg/
ml) for 1 h and stimulated by PMA (40 nM) plus A23187 (1 μM) for 4 h. The mRNA expression level of IL-6 (A) and IL-8 (B) 
was determined by quantitative reverse transcriptase PCR. The concentration of specific inhibitors of ERK (PD98059), JNK 
(SP600125) and NF-κB (MG-132) used in these studies was 50 μM, 10 μM and 100 μM, respectively. Values shown are Mean ± 
SD of four independent experiments and differ without a common letter P < 0.01.
 Journal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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Effect of POMx on the production of pro-inflammatory cytokines in PMACI-stimulated KU812 cells Figure 2
Effect of POMx on the production of pro-inflammatory cytokines in PMACI-stimulated KU812 cells. KU812 cells 
(3 × 106 cells ml-1) were pretreated with POMx (20–100 μg/ml) for 1 h and stimulated by PMA (40 nM) plus A23187 (1 μM) for 
12 h. The production level of IL-6 (A) and IL-8 (B) was determined by a sandwich ELISA. Values shown are Mean ± SD of four 
independent experiments and differ without a common letter P < 0.05, P < 0.001.Journal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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Effect of POMx on the MAPKs phosphorylation in PMACI-stimulated KU812 cells Figure 3
Effect of POMx on the MAPKs phosphorylation in PMACI-stimulated KU812 cells. After pretreatment with POMx 
(20–100 μg/ml) for 1 h at 37°C, KU812 cells (3 × 106 cells ml-1) were stimulated by PMA (40 nM) plus A23187 (1 μM) for 2 h, 
then the phosphorylation of JNK (p54/p46), and ERK (p44/42) was determined by Western blot analysis. Image were digitally 
captured and the band intensities (pixels/band) were obtained using the Un-Scan-It software and are expressed in arbitrary 
O.D. units. Data shown is cumulative of two experiments and the O.D. values are mean ± SD. *P < 0.001 Vs PMACI alone (P-
JNK/ERK-p54), #P < 0.001 Vs PMACI alone (P-JNK/ERK-p46).
gJournal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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Treatment with POMx inhibited the activation and DNA binding activity of NF-κB in PMACI-stimulated KU812 cells Figure 4
Treatment with POMx inhibited the activation and DNA binding activity of NF-κB in PMACI-stimulated 
KU812 cells. KU812 cells (3 × 106 cells ml-1) were pretreated with POMx (20, 40 μg/ml) for 1 h and stimulated by PMA (40 
nM) plus A23187 (1 μM) for 2 h. (A) IκBα degradation and NF-κB translocation was analyzed by Western immunoblotting 
using antibodies specific for the p65 subunit of NF-κB (C-NF-κB, cytoplasmic NF-κB; N-NF-κB, nuclear NF-κB). (B) Band 
intensities were obtained as described above Data shown is cumulative of two experiments and the O.D. values (pixels/band) 
are mean ± SD. *P < 0.001 Vs PMACI alone (N-NF-κB), #P < 0.05 Vs PMACI alone (C-NF-κB), ##P < 0.05 Vs PMACI alone 
(IκBα). (C) NF-κB luciferase assay: Cells were transiently transfected with the NF-κB luciferase reporter construct or empty 
vector and the NF-κB-dependent transcriptional activity was determined by luciferase activity using a commercially available kit 
(Promega). Each bar represents the mean ± SD of three independent experiments. *P < 0.001 Vs PMACI alone.Journal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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KU812 cells release an array of inflammatory cytokines
and chemokines especially IL-6 and IL-8 which have the
potential to cause inflammation and tissue remodeling
[28]. IL-6 is a multifunctional cytokine that plays a key
role in immune response, growth and differentiation of B-
and T-cells, hematopoiesis and the induction of hepatic
acute phase plasma proteins [29]. Increased tissue levels
of IL-6 in diseases like arthritis [30], psoriasis [31], sclero-
derma [32], and delayed pressure urticaria have been
demonstrated [33]. Binding of IL-6 to its receptor is
known to induce IL-6-dependent signal transduction in
mast cells and basophils [34]. IL-6 is also an important co-
factor in IL-4 dependent IgE synthesis. IL-6 is also pro-
duced by mast cells and basophils and its local accumula-
tion in arthritic joints is associated with the chronic
response [35]. IL-8 is best known for its potent chemoat-
tractant activity on neutrophils and T-cells and their func-
tions [36]. Like IL-6, IL-8 has been shown to be increased
in various inflammatory diseases, including arthritis, that
are characterized by elevated mast cells number [35].
Interestingly, many reports have shown that human mast
cells and basophils secrete both IL-6 and IL-8 [37,38].
Polyphenols are plant molecules entering in our bodies
through diet. The relationship between polyphenol-rich
food consumption and reduced possibility of being
affected by some diseases has attracted increasing interest
from consumers, food manufacturers and nutritional sci-
entists. Fruit and vegetable consumption may prevent
cancers [39] and stroke [40], whereas wine consumption
may have similar effect in preventing coronary heart dis-
ease [41], and prostate cancer [42]. Soy consumption may
have protective effects against cancerous cells [43] and
osteoporosis [44] and tea polyphenols may prevent differ-
ent cancers [45] and arthritis [46]. Pomegranate fruit is a
rich source of polyphenols. Hydrolysable tannins are pre-
dominant polyphenols found in pomegranate juice and
account for 92% of its antioxidant activity [47]. Pome-
granate seeds are rich in sugars, polyunsaturated fatty
acids, vitamins, polysaccharides, polyphenols, and miner-
als and have high antioxidant activity. When crushed and
dried, the pomegranate seeds produce an oil with 80%
punicic acid, the 18-carbon fatty acid, along with the iso-
flavone genistein, the phytoestrogen coumestrol, and the
sex steroid estrone. The seed coat of the fruit contains del-
phinidin-3-glucoside, delphinidin-3,5-diglucoside, cyani-
din-3-glucoside, cyanidin-3,5-diglucoside, pelargonidin-
3-glucoside, and pelargonidin-3,5-diglucoside with del-
phinidin-3,5-diglucoside being the major anthocyanin in
pomegranate juice [48]. Pomegranate fruit extract are also
rich in oligomers which upon hydrolysis produce ellagic
acid, which is a potent antioxidant, anticancer and antia-
therosclerotic agent [22,49,50]. Studies have also shown
that the antioxidant capacity of pomegranate juice is three
times that of the popular antioxidant-containing bever-
ages such as red wine and green tea, presumably due to the
presence of hydrolyzable tannins in the rind, along with
anthocyanins and ellagic acid derivatives [47]. In a com-
parative analysis, anthocyanins from pomegranate fruit
were also shown to possess higher antioxidant activity
than vitamin-E (α-tocopherol), ascorbic acid and β-caro-
tene [51]. Pomegranate extract has also been shown to
protect from NSAID and ethanol-induced gastric ulcera-
tion [52]. Repeated administration of high doses of a
hydroalcoholic extract of pomegranate whole fruit or its
constituent ellagitannin punicalagin were non toxic in the
dosages commonly employed in traditional medicine sys-
tems [53,54]. Flavonoid rich fractions of pomegranate
fruit extract have also been shown to exert antiperoxida-
tive effect as their administration significantly decreased
the concentrations of malondialdehyde, hydroperoxides
and enhanced the activities of catalase, superoxide dis-
mutase, glutathione peroxidase and glutathione reductase
in the liver [55,56]. We recently reported in vivo efficacy of
pomegranate constituents and/or their metabolites that
become bioavailable after oral ingestion pomegranate
fruit extract [22]. Here we show that POMx, a hydrolysa-
ble tannin rich extract of pomegranate, inhibited the gene
expression and production of pro-inflammatory cytokines
IL-6 and IL-8 by a human mast cell – like KU812 cells. The
MAPK cascade is one of the important signaling pathways
in an inflammatory response [57]. The signaling pathways
characterized by MAPKs p38, ERK, and JNK, are known to
play a potential role in the regulation of inflammatory
response [58]. They are the key players in the molecular
and cellular events associated with the pathogenesis of
inflammatory arthritis and are being studied as a rational
target of drug design for arthritis therapy [59]. In the
present study, POMx specifically inhibited the PMACI-
induced activation of JNKp54/p46- and ERKp44/p42-
sub-groups of MAPK and inhibited the production of IL-6
and IL-8 by KU812 cells. In addition, JNK- and ERK-spe-
cific inhibitors, SP600125 and PD98059 also reduced IL-
6 and IL-8 gene expression, respectively, in KU812 cells.
These data suggest that compounds present in POMx have
the potential to inhibit the inflammatory stimuli-induced
JNK- and ERK-MAPK activation and inhibit the down-
stream IL-6 and IL-8 gene and protein expression.
Activation of the master transcription factor NF-κB leads
to the coordinated expression of many genes that encode
cytokines, chemokines, enzymes, and adhesion molecules
involved in mediator synthesis and the further amplifica-
tion and perpetuation of the inflammatory reaction [16].
Expression of IL-6 and IL-8 gene is dependent on the acti-
vation of transcription factor NF-κB [60]. Because sup-
pression of NF-κB activation has been linked with anti-
inflammatary activity, we postulated that POMx mediates
its inhibitory effects on IL-6 and IL-8 expressions at least
in part, through the suppression of NF-κB activity. Activa-Journal of Inflammation 2009, 6:1 http://www.journal-inflammation.com/content/6/1/1
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tion of NF-κB requires phosphorylation and proteolytic
degradation of the inhibitory protein IκBα, an endog-
enous inhibitor that binds to NF-κB in the cytoplasm and
its degradation expose the nuclear localization signal
(NLS) and allows the NF-κB to translocate to the nucleus
and bind the promoter of target genes [61]. In PMA plus
A23187-stimulated KU812 cells, POMx inhibited the deg-
radation of IκBα and nuclear translocation of the p65 NF-
κB (Fig. 4A &4B). In addition, DNA binding activity of
NF-κB as demonstrated by the reporter assays (Fig. 4C)
was also inhibited in these cells. These data indicate that
POMx attenuates the inflammatory stimuli-induced acti-
vation and DNA binding activity of NF-κB in KU812 cells.
As IL-6 and IL-8 genes are NF-κB dependent genes, this
also inhibit their expression and production in PMACI-
stimulated KU812 cells.
Cytokines produced by mast cell and basophils are associ-
ated with the progress of inflammation. Both basophils
and mast cells play a major role in the pathogenesis of
inflammatory diseases by releasing several pro-inflamma-
tory mediators. Our results suggest that POMx may regu-
late the pro-inflammatory cytokine expression and
production by mast cells through different mechanisms.
In view of the increasing prevalence of allergic and inflam-
matory diseases such as arthritis, asthma, allergic rhinitis,
and eczema worldwide [16,28], there is a need for novel
and safe treatment and or prevention option for the
underlying inflammation caused by activation of mast
cells and basophils [62]. Mast cells play different roles in
the inflammation by the release of various chemokines
and cytokines via different intracellular signal transduc-
tion pathways [62]. The results obtained in this study pro-
vide new evidence that POMx may contribute to the
prevention and/or treatment of inflammatory diseases by
inhibiting the activation of mast cells.
There is evidence from several studies that supplementa-
tion with POMx improves inflammatory symptoms in vivo
and in vitro [21,48-52,56]. However, the molecular phar-
macological basis for the observed effects has not been
fully uncovered yet. Direct inhibitory effects of plant
extracts or components in other systems have been
reported [63,64], but few have addressed the question of
bioavailability and activity of bioavailable constituents. In
this regard results reported by Schaffer, et al [65] are
important as they showed that after oral ingestion of pyc-
nogenol human plasma contained bioactive compounds
that inhibited the activity of COX-1 and COX-2 in an in
vitro assay. We also wish to point out that the in vivo effi-
cacy of the extract used here has already been shown by us
in an animal model of inflammatory arthritis [21] indicat-
ing that after oral consumption pomegranate metabolites
can exert anti-inflammatory effect in vivo. This gets
strength from our studies showing that after oral con-
sumption of a pomegranate extract, its constituents/
metabolites become bioavailable and inhibit COX-2
activity, PGE2 and NO production in chondrocytes [22]. It
is well documented that fruit or plant extracts are a com-
plex mixture of various constituents and in most of the
instances it is still not clear whether a single compound or
a mixture of compounds is responsible for the reported
effects [65]. However, evidence is accumulating that often
related compounds present in a fruit or herb extract aug-
ment each other's biological effect. For example, it has
been reported that ellagic acid and quercetin (both are
also present in pomegranate) together exert a more pro-
nounced inhibitory effect against cancer cell growth than
either compound alone [66].
Conclusion
Our is the first report that shows POMx inhibits the
inflammatory activity of activated human mast cells like
KU812 cells. The results of the present study indicate that
POMx inhibits PMACI-induced pro-inflammatory
cytokines production via inhibiting the gene expression.
This is achieved by blocking JNK- and ERK-MAPK activa-
tion and NF-κB activation in human KU812 cells. POMx
or POMx-derived compounds may be of value for the
treatment of inflammatory diseases in which mast cells
play an active role.
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